ZLAB250117P15000
- 0.55
- 0.000.00%
Zai Lab Newsroom
Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)
Trump Told Advisers He Wants to Visit China as President
GF SEC: VERTEX JPM meeting update, focusing on the progress in the fields of domestic enterprise pain and kidney disease.
The success of Suzetrigine offers hope for the development of the Nav1.8 target, and based on its inherent mechanism advantages, it is expected to bring a new, safer, and more effective therapy for pain patients.
Sector Update: Health Care Stocks Decline Late Afternoon
Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)
Zai Lab Announces China's NMPA Accepted NDA for KarXT
Zai Lab Limited's (NASDAQ:ZLAB) One-year Returns Climbed After Last Week's 4.4% Gain, Institutional Investors Must Be Happy
Express News | Zai Lab Says China's National Medical Products Administration Has Accepted the NDA For KarXT For Treatment Of Schizophrenia
Express News | Zai Lab Announces Acceptance of New Drug Application for Karxt for the Treatment of Schizophrenia
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $29
Zai Lab's Robust Product Growth and Portfolio Expansion Drive Buy Recommendation
The US stock market fluctuated and then declined, Apple fell by 4%, Taiwan Semiconductor's ADR once rose over 7%, and Luxury Goods stocks along with European and American government bonds increased.
In December, USA's retail sales growth was weaker than expected, but the Philadelphia January manufacturing Index reached its highest level in nearly four years. Federal Reserve Board member Waller predicted that there might be up to four interest rate cuts this year, which lowered USA Treasury yields and the dollar. The S&P experienced its first decline in four days, previously boosted by Banks' Earnings Reports. Taiwan Semiconductor's quarterly report confirmed AI demand, leading to most chip stocks rising. Luxury Goods giant Richemont's earnings surpassed expectations, causing a collective increase among peers that pushed French stocks up over 2%. The China concept index rose against the trend, with DouYu increasing by about 28%. The yen approached 155, Bitcoin hovered around $0.1 million, oil prices fell from a six-month high, and Gold reached its highest in five weeks. As a cold wave hit, Henry Hub Natural Gas surged over 4%.
Hong Kong stocks fluctuated | ZAI LAB (09688) rose nearly 4%. The global Phase 3 study of Vitisolizumab in the China subgroup achieved positive primary results.
ZAI LAB (09688) rose nearly 4%, as of this writing, it increased by 3.75% to 19.38 Hong Kong dollars, with a transaction value of 14.0747 million Hong Kong dollars.
Zai Lab to Seek China Approval for Cervical Cancer Therapy After Positive Trial Data
Express News | Zai Lab Highlights Topline Results For TIVDAK In China Subpopulation Of Global Phase 3 InnovaTV 301 Trial In Patients With Recurrent or Metastatic Cervical Cancer
Express News | Zai Lab Ltd - Tivdak Improves Os, Pfs, and Orr in China Subpopulation
Express News | Zai Lab Ltd - to Submit Nda for Tivdak to Nmpa in Q1 2025
Express News | Zai Lab Announces Positive Topline Results for Tivdak in the China Subpopulation of the Global Phase 3 Innovatv 301 Trial in Patients With Recurrent or Metastatic Cervical Cancer
Bank of America Securities Keeps Their Buy Rating on Zai Lab (ZLAB)
CITIC: Maintain ZAI LAB (09688) "Outperform Industry" rating, Target Price 28.1 Hong Kong dollars.
ZAI LAB announced that it has reached an exclusive collaboration and licensing agreement with Vertex Pharmaceuticals Incorporated (referred to as Vertex) to obtain the rights to develop and commercialize Povetacicept (referred to as Pove) in Greater China and Singapore.